Disrupting IL-17 signaling through bimekizumab therapy may thus compromise host defense mechanisms, contributing to the elevated risk of oral candidiasis (Gaffen and Moutsopoulos, 2020). The gene discussed is IL17A; the disease is oral candidiasis.